ContractCo-Promotion Agreement • September 14th, 2011 • PediatRx Inc. • Pharmaceutical preparations • New Jersey
***Denotes certain parts that have not been disclosed and have been filed separately with the Secretary, Securities and Exchange Commission, and is subject to a confidential treatment request pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
PediatRx enters U.S. co-promotion agreement for AQUORALTMCo-Promotion Agreement • September 14th, 2011 • PediatRx Inc. • Pharmaceutical preparations
CALIFON, NJ – September 14, 2011 – PediatRx Inc. (“PediatRx”) (OTCBB: PEDX), a hospital specialty company with an initial focus on oncology supportive care products, has entered into a U.S. co-promotion agreement with Bi-Coastal Pharmaceutical Corp. for AQUORAL ™, an FDA-cleared, prescription-only treatment for xerostomia (the medical term for dry mouth due to a lack of saliva). Xerostomia can be a debilitating medical condition and is estimated to impact between 35 and 40 million Americans. It is especially prevalent in patients undergoing various treatments for cancer and those with Sjögren’s syndrome. It is also common in the elderly and in patients who are taking prescription medications.
